5Y Capital

5Y Capital is a private equity and venture capital firm based in Shanghai, China, focused on seed, start-up, early venture, and growth capital investments. Founded in 2008 and previously known as Morningside Venture Capital, the firm manages approximately USD 5 billion in dual-currency funds, supported by global investors such as sovereign wealth funds, family offices, and endowments. 5Y Capital primarily invests in various sectors, including healthcare, technology, fintech, media, software, life sciences, and education, with a special emphasis on medical treatment, biotechnology, and digital health. The firm seeks opportunities in China and other emerging markets across Asia and the Pacific, aiming to support entrepreneurs in building innovative companies. 5Y Capital typically makes initial investments exceeding USD 500,000 per portfolio company and operates as a subsidiary of Morningside Group, which has been active in venture capital investments since 1992.

Ka Chang

Managing Director

Zhe Chen

Managing Director

Peter Chen

Managing Director

Yu Cheng

Partner

Lu Huang

Director

Victor Jin

Managing Director

Jiangyun Jin

Managing Director

Ted Xutian Jing

Managing Director

Levi Liu

Partner

Qin Liu

Co-Founder, Investment Director and Board Member

Richard Liu

Founding Partner

Stephanie O'Brien

Investment Professional

Ken Shi

Founding Partner

Yi Sun

Senior Associate

Jerry Tong

Senior Associate

Yunhong Wei

Investor

Yaopeng Xing

Investor

Patricia Zhuoya Yang

Investor

Tony Yeung

Managing Director

Cloris You Youdan

Managing Director

Elwin Yuan

Partner

Yuan Ye

Partner

Fisher Zhang

Partner

Fei Zhang

Partner

Bo Zhang

Managing Director

Past deals in Macau

Luqa Pharmaceuticals

Series A in 2015
Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company focused on the Chinese market, primarily engaged in the acquisition, development, and commercialization of healthcare products. The company offers a diverse portfolio that includes dermatological and oral care products. Its dermatological offerings feature Ebernet, an eberconazole cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. In the oral care segment, Luqa provides Lacteol, a probiotic for infants and immunocompromised patients, and GelX, a medical device for managing oral cavity pain from conditions like mucositis and stomatitis. Other products include GelX Xero for dry mouth relief, Aftacure for oral mucosal lesions, Ialuxid Gel for post-surgical wounds, and Podofilm for benign epithelial formations. Established in 2010 and based in Central, Hong Kong, Luqa Pharmaceuticals is dedicated to enhancing patient quality of life through innovative healthcare solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.